Before starting on Soliris®.

Important safety information for patients
Before you begin Soliris® (eculizumab) treatment, your physician will give you a:

- Medication Guide
- Soliris Patient Safety Information Card

Read this information and ask your physician any questions you may have about Soliris at any time. Your physician will be able to provide you with the best education and support.

Patient Safety Information Card

You will receive a Patient Safety Information Card from your doctor that lists symptoms of a meningococcal infection and what to do if you have one. Your doctor should discuss with you the importance and the proper use of this card. Carry this card at all times and show it to any healthcare professional who treats you. Seek immediate treatment for headache with nausea or vomiting, or headache with fever, even if you do not have your Patient Safety Information Card with you. Your Patient Safety Information Card contains safety guidance for you and your healthcare providers.

Soliris OneSource™ Treatment Support Program

Soliris OneSource is a program offered by Alexion that provides education; assistance with funding options and access to Soliris; and ongoing treatment support for people living with PNH or aHUS, and their caregivers. OneSource is staffed by Alexion Nurse Case Managers who are registered nurses with healthcare and insurance expertise. Alexion Pharmaceuticals developed this program to help make disease awareness and treatment access as easy as possible for you and your healthcare team.

Questions about PNH, aHUS, or Soliris? Just call OneSource at 1.888.SOLIRIS (1.888.765.4747) to speak with an Alexion Nurse Case Manager.

Injection for Intravenous Use
Patient Safety Information Card

You will receive a Patient Safety Information Card from your doctor that lists symptoms of a meningococcal infection and what to do if you have one. Your doctor should discuss with you the importance and the proper use of this card.

Carry this card at all times and show it to any healthcare professional who treats you. Seek immediate treatment for headache with nausea or vomiting, or headache with fever, even if you do not have your Patient Safety Information Card with you. Your Patient Safety Information Card contains safety guidance for you and your healthcare providers.

PATIENT SAFETY INFORMATION CARD

Important Safety Information for Patients Taking Soliris®

Soliris can lower the ability of your immune system to fight infections, especially meningococcal infection, which requires immediate medical attention. If you experience any of the following symptoms, you should immediately call your doctor or seek emergency medical care, preferably in a major emergency medical care center:

Soliris OneSource™ Treatment Support Program

Soliris OneSource is a program offered by Alexion that provides education; assistance with funding options and access to Soliris; and ongoing treatment support for people living with PNH or aHUS, and their caregivers. OneSource is staffed by Alexion Nurse Case Managers who are registered nurses with healthcare and insurance expertise. Alexion Pharmaceuticals developed this program to help make disease awareness and treatment access as easy as possible for you and your healthcare team.

Questions about PNH, aHUS, or Soliris? Just call OneSource at 1.888.SOLIRIS (1.888.765.4747) to speak with an Alexion Nurse Case Manager.
For Discussion With Patients—
Important Safety Information

MEDICATION GUIDE
Soliris® (so-leer-is)
(eculizumab)

Read the Medication Guide before you start Soliris and before each infusion. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment. Talk to your doctor if you have any questions about your treatment with Soliris.

What is the most important information I should know about Soliris?
Soliris is a medicine that affects your immune system. Soliris can lower the ability of your immune system to fight infections.

- Soliris increases your risk of getting serious and life-threatening meningococcal infections
  Meningococcal infections may quickly become life-threatening and cause death if not recognized and treated early.

1. You must receive meningococcal vaccination at least 2 weeks before your first dose of Soliris unless you have already had this vaccine. If your doctor decides that urgent treatment with Soliris is needed, you should receive meningococcal vaccination as soon as possible.

2. If you had a meningococcal vaccine in the past, you might need additional vaccination before starting Soliris. Your doctor will decide if you need additional meningococcal vaccination.

3. Meningococcal vaccines do not prevent all meningococcal infections. Call your doctor or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection:
   - headache with nausea or vomiting
   - headache and a fever
   - headache with a stiff neck or stiff back
   - fever
   - fever and a rash
   - confusion
   - muscle aches with flu-like symptoms
   - eyes sensitive to light

Want to learn more about Soliris®?
Visit www.Soliris.net or www.solirisrems.com
Call 1.888.SOLIRIS (1.888.765.4747) for information regarding Soliris and the Soliris REMS.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS
Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.

- Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.

- Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of Soliris, unless the risks of delaying Soliris therapy outweigh the risks of developing a meningococcal infection. [see Warnings and Precautions (5.1) for additional guidance on the management of the risk of meningococcal infection.]

- Monitor patients for early signs of meningococcal infections, and evaluate immediately if infection is suspected.

Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris REMS prescribers must enroll in the program. Enrollment in the Soliris REMS program and additional information are available by telephone: 1-888-SOLIRIS (1-888-765-4747) or at solirisrems.com.

Injection for Intravenous Use
Injection for Intravenous Use
Your doctor will give you a Patient Safety Card about the risk of meningococcal infection. Carry it with you at all times during treatment and for 3 months after your last Soliris® dose. Your risk of meningococcal infection may continue for several weeks after your last dose of Soliris. It is important to show this card to any doctor or nurse who treats you. This will help them diagnose and treat you quickly.

Soliris is only available through a program called the Soliris REMS. Before you can receive Soliris, your doctor must:

- enroll in the Soliris REMS program
- counsel you about the risk of meningococcal infection
- give you information about the symptoms of meningococcal infection
- give you a Patient Safety Card about your risk of meningococcal infection, as discussed above.
- make sure that you are vaccinated with a meningococcal vaccine

Soliris may also increase the risk of other types of serious infections. If your child is treated with Soliris, make sure that your child receives vaccinations against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib).

What is Soliris?

Soliris is a prescription medicine called a monoclonal antibody. Soliris is used to treat people with:

- a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH affects red blood cells.
- a disease called atypical Hemolytic Uremic Syndrome (aHUS). aHUS affects the blood system, kidney, and sometimes other body organs.

Soliris works by blocking part of your immune system. This can help your symptoms but it can also increase your chance for infection.

It is important that you:

- have all recommended vaccinations before you start Soliris
- stay up-to-date with all recommended vaccinations during treatment with Soliris
For Discussion With Patients—Important Safety Information (continued)

Who should not receive Soliris®?
Do not receive Soliris if you:

- have a meningococcal infection
- have not been vaccinated against meningitis infection, unless your doctor decides that urgent treatment with Soliris is needed. See “What is the most important information I should know about Soliris?”

What should I tell my doctor before receiving Soliris?
Before receiving Soliris, tell your doctor if you:

- have an infection or fever
- are pregnant or plan to become pregnant. It is not known if Soliris will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if Soliris passes into your breast milk.

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How will I receive Soliris?

- Soliris is given through a vein (I.V. or intravenous infusion) usually over 35 minutes in adults and 1-4 hours in pediatric patients. If you have an allergic reaction during your Soliris infusion, your doctor may decide to give Soliris more slowly or stop your infusion.
- If you are an adult, you will usually receive a Soliris infusion by your doctor:
  — weekly for five weeks, then
  — every 2 weeks
- If you are less than 18 years of age, your doctor will decide how often you will receive Soliris depending on your age and body weight.
- After each infusion, you should be monitored for one hour for allergic reactions. See “What are the possible side effects of Soliris?”
- If you forget or miss a Soliris infusion, call your doctor right away.
If you have PNH, your doctor will need to monitor you closely for at least 8 weeks after stopping Soliris®. Stopping treatment with Soliris may cause breakdown of your red blood cells due to PNH.

Symptoms or problems that can happen due to red blood cell breakdown include:

- drop in the number of your red blood cell count
- drop in your platelet count
- confusion
- chest pain
- kidney problems
- blood clots
- difficulty breathing

If you have aHUS, your doctor will need to monitor you closely during and for at least 12 weeks after stopping treatment for signs of worsening aHUS symptoms or problems related to abnormal clotting (thrombotic microangiopathy).

Symptoms or problems that can happen with abnormal clotting may include:

- stroke
- confusion
- seizures
- chest pain (angina)
- difficulty breathing
- kidney problems
- swelling in arms or legs
- a drop in your platelet count

What are the possible side effects of Soliris?

Soliris can cause serious side effects, including:

- See “What is the most important information I should know about Soliris?”
- **Serious allergic reactions.** Serious allergic reactions can happen during your Soliris infusion. Tell your doctor or nurse right away if you get any of these symptoms during your Soliris infusion:
  - chest pain
  - trouble breathing or shortness of breath
  - swelling of your face, tongue, or throat
  - feel faint or pass out

If you have an allergic reaction to Soliris, your doctor may need to infuse Soliris more slowly, or stop Soliris. See “How will I receive Soliris?”
For Discussion With Patients—Important Safety Information (continued)

Common side effects in people with PNH treated with Soliris® include:

- headaches
- runny nose and colds
- sore throat
- back pain
- nausea

Common side effects in people with aHUS treated with Soliris include:

- headache
- diarrhea
- high blood pressure
- common cold (upper respiratory infection)
- abdominal pain
- vomiting
- nasopharyngitis
- low red blood cell count
- cough
- peripheral edema
- nausea
- urinary tract infection
- pyrexia

Tell your doctor about any side effect that bothers you or that does not go away. These are not all the possible side effects of Soliris. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. To report any suspected adverse event experience, contact Alexion Pharmaceuticals Inc. at 1.844.259.6783 or report to the FDA at 1.800.FDA.1088.
General information about Soliris®

Medicines are sometimes prescribed for conditions other than those listed in a Medication Guide. This Medication Guide summarizes the most important information about Soliris. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Soliris that is written for healthcare professionals.

What are the ingredients in Soliris?

Active ingredient: eculizumab

Inactive ingredients: sodium phosphate monobasic, sodium phosphate dibasic, sodium chloride, polysorbate 80 (vegetable origin) and Water for Injection.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured by Alexion Pharmaceuticals, Inc.
100 College Street, New Haven, CT 06510 USA.
Revised: 1/2017
Want to learn more about Soliris®?

- Visit www.Soliris.net or www.solirisrems.com
- Call 1.888.SOLIRIS (1.888.765.4747) for information regarding Soliris and the Soliris REMS.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS
Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.

- Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
- Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of Soliris, unless the risks of delaying Soliris therapy outweigh the risks of developing a meningococcal infection. [see Warnings and Precautions (5.1) for additional guidance on the management of the risk of meningococcal infection.]
- Monitor patients for early signs of meningococcal infections, and evaluate immediately if infection is suspected.

Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris REMS prescribers must enroll in the program. Enrollment in the Soliris REMS program and additional information are available by telephone: 1-888-SOLIRIS (1-888-765-4747) or at solirisrems.com.

The most frequently reported adverse reactions in the PNH randomized trial (≥10% overall and greater than placebo) are: headache, nasopharyngitis, back pain, and nausea.

The most frequently reported adverse reactions in aHUS single arm prospective trials (≥20%) are: headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, peripheral edema, nausea, urinary tract infections, pyrexia.

Please see full prescribing information for Soliris, including boxed WARNING regarding serious meningococcal infection.